15 results about "Immunity disorders" patented technology

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The invention provides an application of lactobacillus rhamnosus in preparation of a probiotic preparation for regulating weightlessness immune disorder. The application of the lactobacillus rhamnosus in preparation of the probiotic preparation for regulating weightlessness immune disorder proves that the lactobacillus rhamnosus can regulate immune disorder caused by tail suspension simulation weightlessness and can be used for preparing the probiotic preparation for preventing or treating weightlessness immune disorder, a novel probiotic preparation is provided, and the lactobacillus rhamnosus can be used for preparing the probiotic preparation for preventing or treating weightlessness immune disorder. The medicine is suitable for preventing and treating immune diseases generated by astronauts subjected to long-term or short-term space flight.

The invention belongs to the technical field of animal nutrition and feed, discloses an application of a Fuzhuan tea extract in prevention of vomitoxin-caused piglet health injury, and particularly relates to an application of the Fuzhuan tea extract as a feed additive in prevention or improvement of piglet health injury. The feed additive can effectively reduce negative effects on weaned piglets caused by excessive vomitoxin in the feed, wherein the negative effects comprise growth performance reduction, diarrhea rate increase, intestinal morphology damage, intestinal cell proliferation inhibition, intestinal epithelial barrier injury, immune disorder, abnormal liver function and excessive oxidative stress and inflammatory response.

The purpose of the present invention is to control the number of peripheral regulatory T cells in the intestinal tract to thereby establish a novel means for treating a disease relating to the cells. For this purpose, provided is a therapeutic drug for a disease, said drug comprising a substance capable of controlling the number of peripheral regulatory T cells in the intestinal tract and being characterized in that the aforesaid substance is an activator or suppressor of the hepatic branch of vagal afferent pathway, an activator or suppressor of left vagal efferent pathway, or an agonist or antagonist of muscarinic acetylcholine receptor.

To regulate the number of peripheral regulatory T cells in the intestinal tract and to provide a new means for treating diseases associated with the cells.SOLUTION: A therapeutic agent for a disease, comprising a substance having an effect of regulating the amount of peripheral regulatory T cells in the intestinal tract, wherein the substance is a substance that activates or suppresses the hepatic vagal afferent pathway, a substance that activates or suppresses the left vagal efferent pathway, or an agonist or antagonist of a muscarinic acetylcholine receptor.SELECTED DRAWING: None

To provide an anti-blood dendritic cell antigen 2 antibody and its use. [Solution] Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods for using the above antibodies and antibody fragments to induce plasmacytoid dendritic cell death, inhibit the production or secretion of inflammatory cytokines and chemokines, and treat or prevent immune disorders such as inflammatory and autoimmune conditions. (i) an isolated antibody or its antigen-binding fragment that selectively binds to the extracellular domain of human BDCA2, and (ii) competes with BIIB059 for binding to the extracellular domain of human BDCA2.

The present invention provides an anti-CXCR6 antibody and the use thereof. The anti-CXCR6 antibody can bind to CXCR6 with high affinity and high specificity, has cross-species binding activity to both human CXCR6 and monkey CXCR6, is a clearing antibody targeting CXCR6, and has the potential of treating inflammation or immune disorder diseases. Compared with existing CXCR6 antibodies, the anti-CXCR6 antibody involves lower cell non-specific binding activity, lower off-target toxicity and higher safety.

The application discloses a composition for relieving vaginitis by simultaneously activating immune regulation and antioxidant pathways, and belongs to the technical field of microorganisms. The application screens a composite strain containing a strain of Paracaseolovis casei CCFM1316 and a strain of Paracaseolovis casei CCFM1317, and the composition containing the composite strain has the effect of repairing immune disorders, oxidative damage and other related symptoms caused by vaginitis, which is specifically embodied in: regulating the immune response of the mouse vagina; activating the TLR-4 / MyD88 pathway, and reducing the IL-1beta concentration of the vaginal tissue to 29.79 ng / L; improving the oxidative stress of the mouse vagina; and increasing the Nrf2 of the vaginal tissue to 36.58 ng / L. Therefore, the composition of the Paracaseolovis casei CCFM1316 and the Paracaseolovis casei CCFM1317 has great application prospect in products for improving and repairing the inflammatory response and oxidative damage caused by vaginitis.

The invention discloses application of yellow tea polyphenol in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of biological medicine preparation, animal experiments prove that the yellow tea polyphenol can reduce the DAI index of DSS-induced colitis mice and relieve weight loss and colon shortening. By adopting the yellow tea polyphenol provided by the invention, inflammatory response, tissue damage and immune disorder related to colitis can be relieved; the pathological state of colon tissue is improved; therefore, the effect of treating and preventing the colitis is achieved, and the traditional Chinese medicine composition has an extremely wide application prospect.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.

The application discloses lactobacillus johnsonii capable of orally assisting in relieving vaginitis and improving skin aging, and belongs to the technical field of microorganisms.The lactobacillus johnsonii is separated from vaginal secretions of healthy women, has the effects of repairing immune disorders caused by vaginitis and skin aging of mice with vaginitis, and is specifically reflected in the following aspects: reducing the content of IL-1beta in cell supernatant; improving inflammatory reactions of mouse vaginas; reducing the expression of TLR-4 mRNA and the level of TNF-alpha in vaginal tissues; enhancing the anti-aging ability of mouse skin; reducing the expression of MAPK / AP-1 / MMP-1 mRNA, increasing the content of Col I and Col III in skin; improving pathological characteristics of mouse vaginas and reducing the load of pathogenic bacteria.Therefore, the lactobacillus johnsonii has great application prospects in products for improving and repairing inflammatory damage caused by vaginitis and skin health problems of mice with vaginitis.

The invention relates to the technical field of medicines, and particularly discloses a laggera alata extract-containing composition for treating rheumatoid arthritis and a preparation method thereof. The laggera alata extract-containing composition for treating rheumatoid arthritis is prepared from the following raw materials in parts by weight: 20 to 40 parts of laggera alata extract, 5 to 10 parts of curcumin, 3 to 7 parts of icariin, 8 to 15 parts of phosphatidylcholine, 10 to 20 parts of polyethylene glycol-400, 3 to 8 parts of hyaluronic acid, 2 to 5 parts of chitosan and 5 to 12 parts of mannitol. The preparation method comprises the following steps: preparing the extract; preparing a compound; preparing a suspension; and forming the preparation. According to the composition disclosed by the invention, an active system is constructed by adopting the laggera alata extract, curcumin and icariin, synergistic effects are respectively formed aiming at different pathological links such as oxidative stress imbalance of rheumatoid arthritis, abnormal secretion of inflammatory factors, immune disorder and cartilage injury, and the effects of multi-mechanism synchronous intervention and targeted enrichment are achieved.

The present invention provides universal immunotherapy compositions useful for targeted therapy of cancer and other immune disorders.

The invention discloses oral spirulina delivery hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The delivery hydrogel takes spirulina platensis as a raw material, and is added into network-shaped hydrogel formed by xanthan gum / konjac glucomannan / sodium alginate in a combined manner. The method is easy to implement, safe in component and high in encapsulation efficiency. The composite hydrogel has the following effects: after oral administration, the spirulina can be protected to completely pass through the stomach, the intestinal retention is prolonged, and the slow release of the medicine at the focus part is realized; according to the present invention, with the application of the polypeptide, the oxidative stress and the intestinal inflammation can be alleviated, and the expression of the tight junction protein can be significantly recovered so as to enhance the barrier integrity and limit the inflammation leakage, such that the whole body immune homeostasis conversion can be achieved, the good safety and the good compliance can be provided, and the clinical transformation potential as the systemic chronic inflammatory disease adjuvant therapy strategy can be represented; the traditional Chinese medicine composition is especially suitable for diseases with pathological characteristics of intestinal flora imbalance or immune disorder.

The application relates to the technical field of pharmaceutical preparations, in particular to a sustained-release preparation of isopropyl inosine and a preparation method and application thereof, and the sustained-release preparation of isopropyl inosine comprises a tablet core and a coating film covering the tablet core; wherein the tablet core comprises the following components in percentage by mass: 70%-74.35% of isopropyl inosine, 20%-25% of a hydrophilic gel matrix material, 5%-14.35% of a filling agent, 0.5%-2% of a disintegrating agent and 0.15%-0.5% of a lubricant; the coating film comprises the following components in percentage by mass: 70%-75% of a film control material, 10%-20% of a pore-forming agent and 10%-20% of a plasticizer; the weight of the coating film is 5%-8% of the weight of the tablet core. The application provides the sustained-release preparation of isopropyl inosine and a preparation method and application thereof; the sustained-release preparation of isopropyl inosine plays an anti-inflammatory and joint protection role by regulating T / B lymphocyte activity and inhibiting inflammatory factor release, and makes up for the defects of traditional arthritis treatment drugs, i.e. only relieving symptoms and being unable to regulate immune disorders.